Allan Kevin C, Kindy Alexie E, Yuan Alex
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
J Vitreoretin Dis. 2025 Jul 17:24741264251356289. doi: 10.1177/24741264251356289.
To describe a case of cystoid macular edema (CME) caused by paclitaxel, a first-line chemotherapeutic for invasive breast cancer. A single case was presented. CME developed shortly after initiation of paclitaxel; 7 months after discontinuation, improvement was seen. However, the patient's visual acuity never recovered. Changes consistent with macular telangiectasia, which may have been potentiated by paclitaxel toxicity, were seen on multimodal imaging. This is the first reported case of irreversible vision loss after paclitaxel treatment without evidence of phototoxicity. Paclitaxel may exacerbate underlying macular telangiectasia, resulting in ellipsoid zone loss after recovery from CME.
描述一例由紫杉醇（一种浸润性乳腺癌的一线化疗药物）引起的黄斑囊样水肿（CME）病例。报告了1例病例。CME在开始使用紫杉醇后不久出现；停药7个月后有所改善。然而，患者的视力从未恢复。多模态成像显示存在与黄斑毛细血管扩张一致的变化，这可能因紫杉醇毒性而加重。这是首例报道的紫杉醇治疗后出现不可逆视力丧失且无光毒性证据的病例。紫杉醇可能会加重潜在的黄斑毛细血管扩张，导致CME恢复后椭圆体带丧失。
